NeOnc Technologies schedules FDA end-of-Phase 1 meeting for NEO212
The Nov. 17, 2026 in-person Type B meeting will cover Phase 2 study design, dose selection, endpoints and evidence for a future marketing application.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
NeOnc Technologies schedules FDA end-of-Phase 1 meeting for NEO212
The meeting is set for Nov. 17, 2026. The company said Phase 1 results showed durable disease control in two heavily pretreated brain cancer patients.